top of page

New opportunities in bladder treatments.

As part of UroPharma’s development, Urinary Tract Infections are a main focal point. We are please to post our joint collaboration providing a better understanding of the future of direct (non-oral) treatments for bladder and Urinary Tract Infections (UTI). What does this mean?

  • From a clinical perspective this is a shift in quality of life for the patient and substantially better safety and efficacy.

  • From a marketing perspective this form of treatment opens many new opportunities in bladder treatments.

Download the PDF article here:

S. Glickman et al - Effective Treatments of UTI - Is Intravesical Therapy the Future
Download PDF • 811KB

26 views0 comments

Recent Posts

See All

The urobiome

Following on from revelations that we have a complex symbiotic relationship with our #gut microbiome, the discovery that we also have a #urobiome has attracted much attention. There’s no going back to

"We know almost nothing about managing UTI"

“We know almost nothing about managing UTI.” This assertion went unchallenged at the British Society of #Antimicrobial Chemotherapy multidisciplinary conference of experts last year. Increasingly, we

GAG-layer supplements

From Prof. Scott Glickman: A GAG (#glycosaminoglycan) layer within the #bladder, as a nanometres-thick coating, surely would be less than 2ml. Why do companies sell costly GAG-layer supplements as 50m

bottom of page